Literature Scan
Deep Response With Venetoclax Plus Rituximab
in Relapsed/Refractory CLL
Combining the selective BCL2
inhibitor venetoclax with
rituximab may increase the depth
and durability of response in
patients with relapsed/refractory
chronic lymphocytic leukemia
(CLL), according to a report
from the phase Ib M13-365 study
published in the Lancet Oncology.
John F. Seymour, MBBS, from
the Department of Hematology
at the Peter MacCallum Cancer
Centre in Melbourne, Australia,
and co-authors found that patients
who received the combination
treatment had a response rate of